Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2362997 Target Snapshot

Muscle-type nicotinic acetylcholine receptor · PROTEIN COMPLEX GROUP · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
3Compounds
3Assays
2Approved Drugs
3.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Muscle-type nicotinic acetylcholine receptor shows approved-linked disease relevance led by Neuromuscular Blockade. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P02708. Start with Neuromuscular Blockade, then reuse UniProt P02708 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Neuromuscular Blockade, then reuse UniProt P02708 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
Neuromuscular Blockade

Muscle-type nicotinic acetylcholine receptor shows approved-linked disease relevance led by Neuromuscular Blockade. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with Neuromuscular Blockade because it currently carries approved-linked support. Linked drugs include ATRACURIUM BESYLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Muscle-type nicotinic acetylcholine receptor as ChEMBL target CHEMBL2362997, mapped to UniProt P02708. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Muscle-type nicotinic acetylcholine receptor
PROTEIN COMPLEX GROUP · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2362997
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P02708
Acetylcholine receptor subunit alpha
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Muscle-type nicotinic acetylcholine receptor is the right protein anchor across sources, using UniProt P02708 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Neuromuscular Blockade is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameMuscle-type nicotinic acetylcholine receptor
Target TypePROTEIN COMPLEX GROUP
OrganismHomo sapiens
UniProtP02708
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelAcetylcholine receptor subunit alpha
UniProt AccessionP02708
Component TypeProtein
Sequence Length457 aa

Acetylcholine receptor subunit alpha

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Muscle-type nicotinic acetylcholine receptor, mapped to UniProt P02708. ChEMBL maps the protein component as Acetylcholine receptor subunit alpha. Sequence length is 457 aa.

Mapped IDP02708
Review nameMuscle-type nicotinic acetylcholine receptor
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Muscle-type nicotinic acetylcholine receptor shows approved-linked disease relevance led by Neuromuscular Blockade. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
Neuromuscular Blockade
1 linked drug · 1 direct · 1 efficacy
Linked drugATRACURIUM BESYLATE
Late clinical Phase III
acute respiratory distress syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugCISATRACURIUM BESYLATE
Late clinical Phase III
Back pain
1 linked drug · 1 direct · 1 efficacy
Linked drugROCURONIUM BROMIDE
Clinical signal Phase II
cardiac arrest
1 linked drug · 1 direct · 1 efficacy
Linked drugROCURONIUM BROMIDE
Clinical signal Phase II
Decreased liver function
1 linked drug · 1 direct · 1 efficacy
Linked drugMIVACURIUM CHLORIDE
Mechanism-linked
spinal stenosis
1 linked drug · 1 direct · 1 efficacy
Linked drugROCURONIUM BROMIDE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with Neuromuscular Blockade because it currently carries approved-linked support. Linked drugs include ATRACURIUM BESYLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseNeuromuscular Blockade
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Approved
Assay Mix

Activity Type Distribution

EC503.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL267936 4.52 EC50 30000.0 Approved
CHEMBL3 4.19 EC50 65000.0 Approved
Distribution

pChEMBL Value Distribution

0
5.0
0
5.5
0
6.0
0
6.5
0
7.0
0
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

3
Total Assays
1
Tested Compounds
2
Assay Types
Functional — 2 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 1 4.2
Binding — 1 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 1 4.5

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine